✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Urelumab is an investigational drug.
There have been 8 clinical trials for Urelumab. The most recent clinical trial was a Phase 1 trial, which was initiated on May 16th 2017.
The most common disease conditions in clinical trials are Lymphoma, B-Cell, Leukemia, Lymphoid, and Urinary Bladder Neoplasms. The leading clinical trial sponsors are Bristol-Myers Squibb, Sidney Kimmel Comprehensive Cancer Center, and Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
There are twenty-five US patents protecting this investigational drug and three hundred and twenty international patents.
Recent Clinical Trials for Urelumab
|Phase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid Tumors||Clinica Universidad de Navarra, Universidad de Navarra||Phase 1/Phase 2|
|Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer||Bristol-Myers Squibb||Phase 1|
|Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer||University of Chicago||Phase 1|
Top disease conditions for Urelumab
Top clinical trial sponsors for Urelumab
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Urelumab||See Plans and Pricing||Immunoregulatory agents||Flexus Biosciences, Inc. (Princeton, NJ)||See Plans and Pricing|
|Urelumab||See Plans and Pricing||Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein||CureVac AG (Tubingen, DE)||See Plans and Pricing|
|Urelumab||See Plans and Pricing||Constructs having a SIRP-.alpha. domain or variant thereof||ALX ONCOLOGY INC. (Burlingame, CA)||See Plans and Pricing|
|Urelumab||See Plans and Pricing||Methods and compositions for treating conditions associated with an abnormal inflammatory responses||First Wave Bio, Inc. (Ann Arbor, MI)||See Plans and Pricing|
|Urelumab||See Plans and Pricing||Compounds and compositions for immunotherapy||BIRDIE BIOPHARMACEUTICALS, INC. (Grand Cayman, KY)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Urelumab||Argentina||AR102536||2034-11-05||See Plans and Pricing|
|Urelumab||Australia||AU2015342940||2034-11-05||See Plans and Pricing|
|Urelumab||Brazil||BR112017008568||2034-11-05||See Plans and Pricing|
|Urelumab||Canada||CA2964290||2034-11-05||See Plans and Pricing|
|Urelumab||Chile||CL2017001124||2034-11-05||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|